Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06668324 · ClinicalTrials.gov registry record
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 134
- Enrollment target
NCT06668324: Completed study, sponsored by Novartis Pharmaceuticals.
NCT06668324 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 134 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06668324 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 134 participants
- Enrollment target
Study Summary
The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
Primary Outcome
Proportion of patients reported local injection-related reactions (including pain, erythema, induration, and pruritus) by using modified Defense and Veterans Pain Rating Scale (DVPRS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2025-09-05 |
What the finished NCT06668324 record still lists
NCT06668324 is an observational study that tracks outcomes without assigning an intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06668324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06668324 about?
NCT06668324 is a clinical study titled "Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation". The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
What is the current status of trial NCT06668324?
This trial is currently completed. The enrollment target is 134 participants. The study started on 2024-11-15. Estimated completion is 2025-09-05.
Who is sponsoring clinical trial NCT06668324?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI